Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Amgen's EVOLVE trial to study impact of Sensipar/Mimpara on mortality, cardiovascular morbidity
August 18th, 2006
Amgen (AMGN) has initiated a largest prospective, randomized clinical trial planned to date in patients with stage five chronic kidney disease (CKD). EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events) is a phase III international, clinical outcomes study designed to determine whether Sensipar/Mimpara (cinacalcet HCl) can effectively reduce the risk of mortality and cardiovascular morbidity in patients with secondary hyperparathyroidism (secondary HPT) and CKD undergoing maintenance dialysis. EVOLVE was announced at the 2006 European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). Cinalcalet HCl is marketed as Sensipar...
Source: Biotech Law Weekly (2006-08-18)
|
